![Mark O’Mahony](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark O’Mahony
Corporate Officer/Principal en LEAP THERAPEUTICS, INC. .
Fortuna: 12 150 $ al 31/05/2024
Cargos activos de Mark O’Mahony
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
LEAP THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2011 | - |
Historial de carrera de Mark O’Mahony
Antiguos cargos conocidos de Mark O’Mahony.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Tolerx, Inc.
![]() Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Corporate Officer/Principal | 23/03/2010 | 19/12/2011 |
LeukoSite, Inc.
![]() LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Corporate Officer/Principal | 01/01/2000 | 01/01/2000 |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2000 | 01/01/2000 |
DecImmune Therapeutics, Inc.
![]() DecImmune Therapeutics, Inc. BiotechnologyHealth Technology DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^ | Corporate Officer/Principal | - | - |
Serono Corp. | Corporate Officer/Principal | - | - |
Formación de Mark O’Mahony.
University College Dublin | Undergraduate Degree |
Boston University | Masters Business Admin |
Estadísticas
Internacional
Estados Unidos | 7 |
Irlanda | 2 |
Israel | 2 |
Operativa
Corporate Officer/Principal | 6 |
Undergraduate Degree | 1 |
Masters Business Admin | 1 |
Sectorial
Health Technology | 6 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
LEAP THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 5 |
---|---|
Tolerx, Inc.
![]() Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
LeukoSite, Inc.
![]() LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Health Technology |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Serono Corp. | |
DecImmune Therapeutics, Inc.
![]() DecImmune Therapeutics, Inc. BiotechnologyHealth Technology DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^ | Health Technology |
- Bolsa de valores
- Insiders
- Mark O’Mahony
- Experiencia